Levels of amyloid-beta monomer and deposited amyloid-beta in the Alzheimer's disease
brain are orders of magnitude greater than soluble amyloid-beta oligomer levels. Monomeric …

More than 10 clinical trials of Aβ immunotherapy are currently underway in patients with
Alzheimer's disease (AD). The aim is to identify safe approaches for the efficacious antibody …

Amyloid β (Aβ) is a small self-aggregating peptide produced at low levels by normal brain
metabolism. In Alzheimer's disease (AD), self-aggregation of Aβ becomes rampant …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

The amyloid cascade hypothesis is a useful framework for therapeutic development in
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …

Alzheimer's disease (AD) is the most common dementia in the industrialized world, with
prevalence rates well over 30% in the over 80-years-old population. The dementia causes …

The amyloid‐β (Aβ) cascade hypothesis of Alzheimer disease (AD) holds that brain
accumulation of Aβ initiates the disease process. Accordingly, drug research has targeted …

Amyloid-beta (Aβ) is suggested to play a causal role in the pathogenesis of Alzheimer's
disease (AD). Immunotherapies are among the most promising Aβ-targeting therapeutic …

The amyloid hypothesis, that established amyloid-β (Aβ) peptide as the primary cause of
Alzheimer's disease (AD) and related dementia, has driven the development of treatments …

As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so
does the need for therapies that slow the progression of the illness. Beta amyloid has long …